Citic Securities Company Limited(600030) about Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company
Special report on the deposit and actual use of raised funds in 2021
Verification opinions
Citic Securities Company Limited(600030) (hereinafter referred to as ” Citic Securities Company Limited(600030) ” and “sponsor”) is the sponsor of Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company (hereinafter referred to as “company” and ” Cansino Biologics Inc(688185) “) for initial public offering and listing. In accordance with the relevant provisions of the measures for the administration of securities issuance and listing recommendation business, the rules for the listing of shares on the science and Innovation Board of Shanghai Stock Exchange, the measures for the continuous supervision of companies listed on the science and Innovation Board (for Trial Implementation), the measures for the Administration of funds raised by listed companies of Shanghai Stock Exchange (revised in 2013), and the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of funds raised by listed companies, The deposit and actual use of the raised funds of Cansino Biologics Inc(688185) as of December 31, 2021 have been verified. The verification results and opinions are as follows:
1、 Basic information of raised funds
With the approval of the reply on Approving the registration of Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company’s initial public offering of shares (Zheng Jian FA FA Zi [2020] No. 1448 document) issued by China Securities Regulatory Commission, the company publicly issued 24800000 ordinary shares (A shares) in Shanghai Stock Exchange, with an issue price of 209.71 yuan per share and a total raised capital of 520080800000 yuan, After deducting all share issuance expenses (excluding value-added tax, including underwriting and recommendation expenses and other issuance expenses) of RMB 22134289235, the net amount of actually raised funds was RMB 497946510765, of which the amount of over raised funds was RMB 397946510765. All the above funds were received on August 6, 2020, The capital verification report (PWC ztyz (2020) No. 0684) was verified by PwC Zhongtian certified public accountants.
As of December 31, 2021, the company has used 279406291656 yuan of raised funds (excluding cash management of idle raised funds), and the balance of unused raised funds is 21897127344 yuan; The net amount of interest income from raised funds and cash management income received by the company after deducting bank charges is 12811866080 yuan, and the balance of raised funds is 231783142424 yuan, including 174000000000 yuan for cash management.
As of December 31, 2021, in addition to the amount of RMB 174000000000 used for cash management, the balance of the company’s special account for raised funds is RMB 57783142424 (including the interest income of raised funds and cash management income minus the net amount of bank charges).
2、 Deposit and management of raised funds
(I) formulation and implementation of fund-raising management system
In order to standardize the management of the company’s raised funds and protect the rights and interests of investors, the management system of Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company’s raised funds is formulated in accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of Shanghai Stock Exchange on the science and innovation board, the measures for the management of raised funds of listed companies on Shanghai Stock Exchange and other relevant laws and regulations, and in combination with the actual situation of the company, Provisions are made on the storage, use, change, management and supervision of the raised funds, and a special account management is implemented for the raised funds.
(II) signing and implementation of tripartite supervision agreement for raised funds
On July 22, 2020, the company and Citic Securities Company Limited(600030) (hereinafter referred to as the “sponsor”) signed the tripartite supervision agreement on the storage of special account for raised funds (hereinafter referred to as the “tripartite supervision agreement”) with Bank Of China Limited(601988) Tianjin Binhai Branch, Shanghai Pudong Development Bank Co.Ltd(600000) Tianjin Branch, China Merchants Bank Co.Ltd(600036) Tianjin branch and China Citic Bank Corporation Limited(601998) Tianjin branch respectively.
(III) storage of raised funds in special account
As of December 31, 2021, the ending balance of the bank account of the company’s raised funds totaled 57783142424 yuan, including the accumulated bank deposit interest and cash management product income of 12811866080 yuan (after deducting the bank handling fee). This amount does not include the balance of idle raised funds for cash management of the company as of December 31, 2021. For details of using idle raised funds for cash management, please refer to part III of this report. Actual use of raised funds this year (IV) cash management of idle raised funds and investment in related products. The specific storage conditions are as follows:
Unit: RMB
Save
Name of deposit bank account opening account number of deposit company signed on December 31, 2021 discussion on the daily deposit balance of the name of the supervision cooperation company
Bank Of China Limited(601988) Co., Ltd. Tianjin Development Cansino Biologics Inc(688185) 2817905327263669745779
West District sub branch
Shanghai Pudong Development Bank Cansino Biologics Inc(688185) 772 Citic Press Corporation(300788) 017 Shenzhen Ecobeauty Co.Ltd(000010) 85 live 14985182107 third party supervision Xiexing Co., Ltd
Tianjin Science and technology sub branch
Discussion on 29586982507 of Cansino Biologics Inc(688185) 772 Citic Press Corporation(300788) 019 Shenzhen Ecobeauty Co.Ltd(000010) 84 phase of Shanghai Pudong Development Yinhuo tripartite Supervision Association Co., Ltd
Tianjin Branch
China Merchants Bank Co.Ltd(600036) Co., Ltd. Tianjin new technology Cansino Biologics Inc(688185) 122905456610202 phase 2901708362
Technology Industrial Park sub branch
China Merchants Bank Co.Ltd(600036) Co., Ltd. Tianjin new technology Cansino Biologics Inc(688185) 1229054566105064822491109
Technology Industrial Park sub branch
China Citic Bank Corporation Limited(601998) Co., Ltd. Binhai New Area Cansino Biologics Inc(688185) 8111401012700554921 phase 36581889
Branch Sales Department
China Citic Bank Corporation Limited(601998) Co., Ltd. Binhai New Area Cansino Biologics Inc(688185) 8111401012900554922 phase 1780450671
Branch Sales Department
Total 57783142424
3、 Actual use of raised funds this year
(I) use of funds for investment projects with raised funds
As of December 31, 2021, in addition to cash management of idle raised funds, the company has used the funds raised from the initial public offering of A-Shares of RMB 279406291656.
(II) early investment and replacement of raised investment projects
As of December 31, 2021, the company has not replaced the self raised funds of the projects invested by raising funds in advance with the raised funds.
(III) temporary replenishment of working capital with idle raised funds
As of December 31, 2021, the company has not used idle raised funds to temporarily supplement working capital.
(IV) cash management of idle raised funds and investment in related products
In order to improve the use efficiency of the company’s idle raised funds and enhance the ability of the raised funds to obtain income, the company held the second meeting of the second board of directors and the second meeting of the second board of supervisors on August 21, 2020 in accordance with the regulatory guidelines for listed companies No. 2 – regulatory requirements for the management and use of raised funds of listed companies and other relevant systems and norms of the CSRC, The proposal on the use of temporarily idle raised funds for cash management was reviewed and approved, and the company was agreed to use temporarily idle raised funds up to RMB 500 million to timely purchase investment products with high security, good liquidity and principal guaranteed agreements (including but not limited to principal guaranteed financial products, structured deposits, call deposits, time deposits, large certificates of deposit, etc.) with a service life of no more than 12 months, Within the above limit and term, it can be used circularly. The board of directors authorizes the chairman of the company to exercise investment decision-making power and sign relevant documents within the validity of the above quota and resolution, and the specific matters shall be organized and implemented by the financial department of the company.
In order to improve the use efficiency of the company’s raised funds, without affecting the construction of the raised funds and the normal operation of the company, the company will reasonably use some idle raised funds for cash management, increase capital income and obtain investment return for the company and shareholders. On August 27, 2021, the company held the sixth meeting of the second board of directors and the eighth meeting of the second board of supervisors, deliberated and approved the proposal on using temporarily idle raised funds for cash management, and agreed that the company would use temporarily idle raised funds up to RMB 350 million to timely purchase with high safety, good liquidity Investment products with Principal Guaranteed agreements (including but not limited to principal guaranteed financial products, structured deposits, call deposits, time deposits, certificates of deposit, etc.) have a service life of no more than 12 months and can be recycled and rolled within the above limit and term. The board of directors authorizes the chairman of the company to exercise investment decision-making power and sign relevant documents within the validity of the above quota and resolution. The specific matters shall be organized and implemented by the Finance Department of the company.
As of December 31, 2021, the balance of idle funds raised by the company’s initial public offering with cash management was RMB 174000000000. The total investment income of the company from cash management with idle raised funds in this year was 4488653652 yuan.
As of December 31, 2021, the outstanding cash management products held by the company are as follows:
Expected serial number trustee type amount (yuan) start and end time income type annualized income
China Citic Bank Corporation Limited(601998) share structure
1 Limited company deposit of 30000000000, breakeven floating 3.25% in Binhai New Area on November 20, 2021 – income type on February 18, 2022
Bank business department
China Citic Bank Corporation Limited(601998) share structure
2 limited company deposits of 14000000000, breakeven floating 3.10% Binhai New Area sub payment on November 30, 2021 – income type on February 28, 2022
Bank business department
Shanghai Pudong Development Bank Co.Ltd(600000) day structure breakeven floating on November 11, 2021
3. Tianjin Science and technology sub branch’s deposit of 7000000000000 – income type 3.20% on February 11, 2022
4 Shanghai Pudong Development Bank Co.Ltd(600000) day structure 40000000000 breakeven floating 3.20% on November 22, 2021
Tianjin Science and technology sub branch sex deposit – income type on February 22, 2022
paragraph
Shanghai Pudong development structure
five
